Background: Although people with HIV might be at risk of severe outcomes from infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; coronavirus 2019 [COVID-19]), regional and temporal differences in SARS-CoV-2 testing in people with HIV across Europe have not been previously described. Methods: We described the proportions of testing, positive test results, and hospitalizations due to COVID-19 between 1 January 2020 and 31 December 2021 in the EuroSIDA cohort and the factors associated with being tested for SARS-CoV-2 and with ever testing positive. Results: Of 9012 participants, 2270 (25.2%, 95% confidence interval [CI] 24.3-26.1) had a SARS-CoV-2 polymerase chain reaction test during the study period (range: 38.3% in Northern to 14.6% in Central-Eastern Europe). People from Northern Europe, women, those aged <40 years, those with CD4 cell count <350 cells/mm3 , and those with previous cardiovascular disease or malignancy were significantly more likely to have been tested, as were people with HIV in 2021 compared with those in 2020. Overall, 390 people with HIV (4.3%, 95% CI 3.9-4.8) tested positive (range: 2.6% in Northern to 7.1% in Southern Europe), and the odds of testing positive were higher in all regions than in Northern Europe and in 2021 than in 2020. In total, 64 people with HIV (0.7%, 95% CI 0.6-0.9) were hospitalized, of whom 12 died. Compared with 2020, the odds of positive testing decreased in all regions in 2021, and the associations with cardiovascular disease, malignancy, and use of tenofovir disoproxil fumarate disappeared in 2021. Among study participants, 58.9% received a COVID-19 vaccine (range: 72.0% in Southern to 14.8% in Eastern Europe). Conclusions: We observed large heterogeneity in SARS-CoV-2 testing and positivity and a low proportion of hospital admissions and deaths across the regions of Europe.

SARS‐CoV‐2 testing, positivity, and factors associated with COVID‐19 among people with HIV across Europe in the multinational EuroSIDA cohort / Fursa, O.; Bannister, W.; Neesgaard, B.; Podlekareva, D.; Kowalska, J.; Benfield, T.; Gerstoft, J.; Reekie, J.; Rasmussen, L. D.; Aho, I.; Guaraldi, G.; Staub, T.; Miro, J. M.; Laporte, J. M.; Elbirt, D.; Trofimova, T.; Sedlacek, D.; Matulionyte, R.; Oprea, C.; Bernasconi, E.; Hadžiosmanović, V.; Mocroft, A.; Peters, L.; Null, Null. - In: HIV MEDICINE. - ISSN 1464-2662. - (2024), pp. 1-14. [10.1111/hiv.13620]

SARS‐CoV‐2 testing, positivity, and factors associated with COVID‐19 among people with HIV across Europe in the multinational EuroSIDA cohort

Guaraldi, G.;
2024

Abstract

Background: Although people with HIV might be at risk of severe outcomes from infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; coronavirus 2019 [COVID-19]), regional and temporal differences in SARS-CoV-2 testing in people with HIV across Europe have not been previously described. Methods: We described the proportions of testing, positive test results, and hospitalizations due to COVID-19 between 1 January 2020 and 31 December 2021 in the EuroSIDA cohort and the factors associated with being tested for SARS-CoV-2 and with ever testing positive. Results: Of 9012 participants, 2270 (25.2%, 95% confidence interval [CI] 24.3-26.1) had a SARS-CoV-2 polymerase chain reaction test during the study period (range: 38.3% in Northern to 14.6% in Central-Eastern Europe). People from Northern Europe, women, those aged <40 years, those with CD4 cell count <350 cells/mm3 , and those with previous cardiovascular disease or malignancy were significantly more likely to have been tested, as were people with HIV in 2021 compared with those in 2020. Overall, 390 people with HIV (4.3%, 95% CI 3.9-4.8) tested positive (range: 2.6% in Northern to 7.1% in Southern Europe), and the odds of testing positive were higher in all regions than in Northern Europe and in 2021 than in 2020. In total, 64 people with HIV (0.7%, 95% CI 0.6-0.9) were hospitalized, of whom 12 died. Compared with 2020, the odds of positive testing decreased in all regions in 2021, and the associations with cardiovascular disease, malignancy, and use of tenofovir disoproxil fumarate disappeared in 2021. Among study participants, 58.9% received a COVID-19 vaccine (range: 72.0% in Southern to 14.8% in Eastern Europe). Conclusions: We observed large heterogeneity in SARS-CoV-2 testing and positivity and a low proportion of hospital admissions and deaths across the regions of Europe.
2024
1
14
SARS‐CoV‐2 testing, positivity, and factors associated with COVID‐19 among people with HIV across Europe in the multinational EuroSIDA cohort / Fursa, O.; Bannister, W.; Neesgaard, B.; Podlekareva, D.; Kowalska, J.; Benfield, T.; Gerstoft, J.; Reekie, J.; Rasmussen, L. D.; Aho, I.; Guaraldi, G.; Staub, T.; Miro, J. M.; Laporte, J. M.; Elbirt, D.; Trofimova, T.; Sedlacek, D.; Matulionyte, R.; Oprea, C.; Bernasconi, E.; Hadžiosmanović, V.; Mocroft, A.; Peters, L.; Null, Null. - In: HIV MEDICINE. - ISSN 1464-2662. - (2024), pp. 1-14. [10.1111/hiv.13620]
Fursa, O.; Bannister, W.; Neesgaard, B.; Podlekareva, D.; Kowalska, J.; Benfield, T.; Gerstoft, J.; Reekie, J.; Rasmussen, L. D.; Aho, I.; Guaraldi, G.; Staub, T.; Miro, J. M.; Laporte, J. M.; Elbirt, D.; Trofimova, T.; Sedlacek, D.; Matulionyte, R.; Oprea, C.; Bernasconi, E.; Hadžiosmanović, V.; Mocroft, A.; Peters, L.; Null, Null
File in questo prodotto:
File Dimensione Formato  
HIV Medicine - 2024 - Fursa - SARS‐CoV‐2 testing positivity and factors associated with COVID‐19 among people with HIV.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 1.02 MB
Formato Adobe PDF
1.02 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1334686
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact